BioMarin Pharmaceutical Inc. expects its third-quarter 2026 results to include approximately $283 million of pre-tax acquired in-process research and development (IPR&D) expense related to its completed acquisition of Alesta Therapeutics B.V. on August 31, 2026. The IPR&D charge and ongoing operating expenses are expected to have an approximately $1.50 unfavorable impact on both GAAP and non-GAAP diluted EPS.
For full-year 2026, BioMarin expects approximately $320 million of total pre-tax charges, including acquired IPR&D and ongoing operating expenses such as transaction and transition costs. Those charges are expected to have an approximately $1.55 unfavorable impact on both GAAP and non-GAAP diluted EPS. The full-year 2026 guidance announced August 6, 2026 did not reflect Alesta; updated guidance is expected in connection with third-quarter results.
BioMarin says it does not forecast acquired IPR&D charges because the occurrence, magnitude and timing of business-development transactions are inherently uncertain. The preliminary, unaudited third-quarter estimates remain subject to financial-statement closing procedures, and results for the quarter ended September 30, 2026 have not been finalized.
BioMarin Pharmaceutical Inc. EVP, Chief R&D Officer Gregory R. Friberg had 4,086 shares delivered or withheld for payment of exercise price or tax liability on September 30, 2026. The reported price was $60 per share. Following the transaction, Friberg directly held 47,732 shares of common stock; the transaction was reported as a disposition.
BioMarin Pharmaceutical Inc. entered into a Settlement and License Agreement with Ascendis Pharma A/S on September 24, 2026, granting Ascendis and its affiliates a non-exclusive, worldwide, transferable, royalty-bearing license to certain BioMarin patents. The license covers research, development, manufacture, use, sale and commercialization of products, methods or services containing C-type natriuretic peptide known as TransCon CNP, navepegritide or Yuviwel, for all current and potential indications.
Ascendis will pay royalties equal to 20% of annual net sales in the United States and 18% of annual net sales in the European Union, Brazil and South Korea, from the first commercial sale in each territory, retroactively as applicable, through May 2030. The agreement supersedes the parties’ term sheet and is deemed effective as of August 28, 2026. The parties will dismiss with prejudice all pending litigation between them relating to the BioMarin Patent Rights.
BioMarin Pharmaceutical Inc. (BMRN) reported that on September 15, 2026 it decided to discontinue development of VOXZOGO for children with Noonan syndrome. The company states this decision followed an assessment of study feasibility and the current treatment landscape, and was not related to the safety or efficacy of VOXZOGO.
BioMarin also reiterates that it uses its investor relations website as a channel for disclosing material non-public information and for complying with Regulation FD.
BIOMARIN PHARMACEUTICAL INC (BMRN) reported that director Robert M. Plenge received a grant of 6,140 shares of common stock in the form of restricted stock units on September 10, 2026, as equity compensation. The grant carries no cash exercise price, and his directly held position after the award is 6,140 shares.
No Rule 10b5-1 trading plan is reported in connection with this grant.
BIOMARIN PHARMACEUTICAL INC (BMRN) filed an initial statement of beneficial ownership (Form 3) for Robert M. Plenge, who is identified as a director of the company. The filing reports no transactions, no derivative positions, and no share holdings for him at this time.
BioMarin Pharmaceutical Inc. (BMRN) reported that its Board of Directors increased the Board size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D. as a director effective September 10, 2026. He will also serve on the Board’s Science and Technology Committee as an independent non-employee director.
On the appointment date, Dr. Plenge received a restricted stock unit grant valued at $400,000 under BioMarin’s 2017 Equity Incentive Plan, based on a pro rata share of the 2026 annual non-employee director award described in the company’s April 21, 2026 proxy statement. The RSUs will vest immediately before the company’s next regular annual meeting of stockholders. BioMarin plans to enter into its standard form indemnification agreement with Dr. Plenge, and states he was not appointed pursuant to any arrangement with another person and has no related party transactions reportable under Regulation S-K Item 404(a).
BIOMARIN PHARMACEUTICAL INC (BMRN) executive George Eric Davis, EVP and Chief Legal Officer, reported selling 17,557 shares of common stock on September 2, 2026 in an open market or private transaction at a weighted average price of $66.284 per share. After this sale, he directly holds 61,003 shares of BioMarin common stock. No Rule 10b5-1 trading plan is reported for this transaction. The footnote states the actual sale prices ranged from $66.271 to $66.39 per share.
BIOMARIN PHARMACEUTICAL INC (BMRN) has a notice of proposed sale of common stock under Rule 144 filed on behalf of officer George Eric Davis. The filing covers up to 17,557 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NASDAQ market.
The shares relate to restricted stock vesting events of 15,595 shares on March 15, 2026 and 1,962 shares on March 17, 2026, both described as compensation. As of September 2, 2026, 193,573,759 shares of common stock were outstanding, and the proposed sale has an aggregate market value of $1,163,755.77.
BioMarin Pharmaceutical Inc. (BMRN) has completed the previously announced acquisition of Alesta Therapeutics B.V. under a Share Purchase Agreement. The transaction closed on August 31, 2026, resulting in Alesta becoming a wholly owned subsidiary of BioMarin.
The Share Purchase Agreement was originally entered into on August 18, 2026 among BioMarin, Alesta’s shareholders, Anaheim SpinCo B.V., and Shareholder Representative Services LLC, acting as representative of the Alesta equityholders.